Characterization of T-cell subpopulations in patients with chronic rhinosinusitis with nasal polyposis

Pascal Ickrath, M.D.,¹ Norbert Kleinsasser, M.D.,¹ Xin Ding,² Christian Ginzkey, M.D.,³ Niklas Beversdorf, M.D.,² Rudolf Hagen, M.D.,¹ Thomas Kerkau, M.D.,² and Stephan Hackenberg, M.D.¹

ABSTRACT

Background: There is an ongoing discussion concerning the potential origins of chronic rhinosinusitis with nasal polyposis (CRSwNP).

Objective: The aim of this study was to quantify subpopulations of T cells in peripheral blood and nasal polyps in CRSwNP to examine their influence on the etiology of this disease.

Methods: Tissue and blood samples were collected from 11 patients who underwent nasal sinus surgery, and these samples were analyzed by multicolor flow cytometry.

Results: There was a significantly lower frequency of $CD4^+$ T-helper (Th) cells and a significantly higher frequency of $CD8^+$ T cells among lymphocytes isolated from nasal polyps compared with peripheral blood mononuclear cells (PBMC). In both T-cell subpopulations, a shift mainly from naive T cells among peripheral blood lymphocytes toward an effector memory and terminally differentiated subtype predominance in nasal polyps was observed. Among $CD4^+$ T cells, the frequencies of cluster of differentiation (CD) 45RA- Forkhead-Box-Protein P3high (FoxP3^{high}) cytotoxic T-lymphocyte-associated Protein 4high $(CTLA-4^{high})$ activated regulatory T (T_{reg}) cells, and CD45RA- Forkhead-Box-Protein P3low (FoxP3^{low}) memory T cells were significantly increased in nasal polyps compared with PBMC.

Conclusion: In this study, we presented a detailed characterization of CD4⁺ and CD8⁺ T-cell subpopulations in patients with CRSwNP. $CD8^+$ T cells were more prominent in nasal polyps than in $CD4^+$ T cells. Both nasal $CD8^+$ T cells and $CD4^+$ T cells predominantly had an effector memory phenotype. Among $CD4^+$ T cells, activated T_{reg} cells were increased in nasal polyps compared with PBMC. The data point toward a local regulation of T-cell composition within the microenvironment of nasal polyps, which might be further exploited in the future to develop novel immunotherapeutic strategies.

(Allergy Rhinol 8:e139-e147, 2017; doi: 10.2500/ar.2017.8.0214)

hronic rhinosinusitis (CRS) is an inflammatory condition of the mucosal nasal tissue that persists over at least 12 weeks or that demonstrates more than four episodes of infections per annum. The development of nasal polyps subdivides CRS into two different groups: CRS with nasal polyposis (CRSwNP) and CRS

The authors have no conflicts of interest to declare pertaining to this article

Address correspondence to Pascal Ickrath, M.D., Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University of Wuerzburg, Josef-Schneider-Str. 11, D-97080 Würzburg, Germany E-mail address: ickrath_p@ukw.de

without nasal polyposis (CRSsNP).1 CRSwNP can be further subclassified into two endotypes, depending on the histologic findings with either eosinophilic or fibrotic (noneosinophilic) cell infiltration. Among white patients in Europe and the United States, the most common subtype is eosinophilic, whereas Asian patients most often develop fibrotic nasal polyps.² The statistics on CRS are heterogeneously discussed in the literature: the prevalence of CRS is described to be \sim 5% (range, 1–19%) whereas the subgroup CRSwNP has a prevalence of $\sim 2\%$.³ There is still an ongoing discussion about the potential origins of nasal polyps, including a chronic inflammatory reaction of the nasal mucosa, anatomic variations that lead to constrictions of draining passages, or an allergic diathesis.

Recently, noninvasive colonization with fungi, including Aspergillus fumigatus and Candida albicans⁴⁻⁶ or with the bacterium Staphylococcus aureus, has been indicated to act as triggers for the development of nasal polyps.^{7,8} Moreover, it is believed that fungal proteins⁴ and/or bacterial superantigens⁹⁻¹¹ induce recruitment of T cells into the nasal mucosa. Apart from the sheer number of T cells recruited, variations in T-lymphocyte subpopulations, especially of regulatory T (T_{reg}) cells,¹²

From the ¹Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University of Wuerzburg, Würzburg, Germany, ²Institute for Virology and Immunobiology, University of Wuerzburg, Würzburg, Germany, and ³Department of Oto-Rhino-Laryngology, Head and Neck Surgery "Otto Körner," University Medical Center Rostock, Rostock, Germany

This work was, in part, supported by a grant from the Deutsche Forschungsgemeinschaft (SFB/TR 124 FungiNet, project C6)

Example 2 This work is published and licensed by OceanSide Publications, Inc. allergyandrhinology.com, and incorporate the Creative Commons License Deed: Attribution - Non-Commercial 4.0 Unported (CC BY-NC 4.0). By accessing the work you hereby accept the terms. Non-commercial uses of the work are permitted without any further permission from OceanSide Publications, Inc., provided the work is properly attributed. Any use of the work other then as authorized under this license or copyright law is prohibited.

are also considered to crucially contribute to the development of nasal polyps. Immunomodulatory properties that induce variations in T-lymphocyte subpopulations, indeed, have been noted both for fungal^{13,14} and for staphylococcal proteins.¹⁵ It is possible to classify T_{reg} cells into two subpopulations, depending on their origin: natural $T_{\rm reg}$ cells from the thymus and peripherally induced T_{reg} cells, which develop from peripheral naive T-helper (Th) cells.^{16,17} A deficiency of peripheral T_{reg} cells can generate a chronic T-cell– mediated immunopathology. Reduced numbers and/or the function of T_{reg} cells were demonstrated to be responsible for different kinds of autoimmune disorders and chronic infections.^{16,18} Even in oncologic studies, the importance of T_{reg} cells has been shown, and many researchers have focused on their influence.19,20

For many years, $T_{\rm reg}$ cells were identified by the surface markers CD4, CD25, and the intracellular transcription factor Forkhead-Box-Protein P3 (FoxP3).²¹ FoxP3 is a key regulator of T_{reg} cell function and development.¹⁶ Miyara *et al.*,²² however, managed to further differentiate T_{reg} cells into subpopulations of CD4⁺ FoxP3⁺ T cells based on the surface marker CD45RA and the checkpoint inhibitor cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4). In this context, resting T_{reg} (r T_{reg}) cells, activated T_{reg} (a T_{reg}) cells, and conventional nonsuppressive memory T cells with a low expression of Forkhead-Box-Protein P3 (FoxP3^{low}) were defined.^{22,23} For identifying these subpopulations and analyzing the differences between peripheral and edaphic T cells, flow cytometry analysis is the method of choice.^{18,22,24,25} The aim of this study was to compare subpopulations of T cells in peripheral blood and nasal polyps of patients with CRSwNP by using an up-todate panel of markers for effector and T_{reg} cell subsets to elucidate their influence on the etiology of this disease.

METHODS

Preparation of Human Lymphocytes

Heparinized blood samples (10 mL) were obtained during surgery by venous puncture from 11 patients who were undergoing nasal sinus surgery, and the samples were transferred to the laboratory. Lymphocytes were separated by density-gradient centrifugation (10 minutes, $1000 \times g$) at room temperature on equal amounts of Ficoll (Biochrom GmbH, Berlin, Germany) by using a membrane-containing 10-mL cell tube (Greiner Bio-One GmbH, Frickenhausen, Germany). After washing twice in phosphate-buffered saline (PBS) solution (Gibco; BRL Life Technologies, Eggenstein, Germany), the cell number and viability were determined by using a cell counter plus analyzer system (CASY TT; Roche Innovatis AG, Reutlingen, Germany) according to the manufacturer's protocol. After centrifugation at 1600 rpm, the cells were frozen to -80° C with 1 mL of freezing medium, which contained 10 parts of fetal calf serum (Linaris Biologische Produkte GmbH, Dossenheim, Germany) and one part of Dimethyl sulfoxide (DMSO) (Carl Roth GmbH + Co. KG, Karlsruhe, Germany).

Preparation of Tissue Samples

All tissue samples were collected during surgery from the 11 patients who were undergoing regular nasal sinus surgery. Polyp tissue specimens were processed to obtain tissue-associated lymphocytes; healthy nasal mucosa served as the control tissue. The polyps were cut into small fragments and mashed through a cell stainer (Greiner Bio-One, Frickenhausen, Germany) from 100 to 40 μ m in PBS solution (Gibco; BRL Life Technologies). After washing twice in PBS solution, the cell number and viability were determined by using a CASY TT system according to the manufacturer's protocol. After centrifugation (5 minutes, 1600 rpm), the cells were frozen to -80° C with 1 mL of freezing medium.

Flow Cytometry Analysis

The following antibodies were used: anti-CD45 Pacific Orange, anti-CD3 R-Phycoerythrin.cyanine dye 7 (PE.Cy7), anti-CD4 Pacific Blue, anti-CD8a Alexa 700, anti-CD28 R-Phycoerythrin (PE), anti-CD45RA Peridinin.Chlorophyll protein-Cyanin5.5 (Per.CP-Cy5.5), anti-C-C chemokine receptor type 7 (CCR7) Alexa 488, anti-CD25 Allophycocyanin (anti-CD25 APC), anti-Human Leukocyte Antigen - antigen D Related (HLA-DR) Alexa 700, anti-CD4 Fluorescein isothiocyanate (FITC), anti-Forkhead-Box-Protein P3 (FoxP3) Pacific Blue and anti-cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) R-Phycoerythrin (PE) (all from BioLegend, San Diego, California). Gating started on forward and side scatter properties, then CD45 was identified. Within this population, CD3⁺ cells were detected, in addition, with Viability Dye 780 (eBioscence, Inc., San Diego, CA) in this step to detect apoptotic cells. Afterward, gating on viable $CD3^+$ $CD4^+$ or $CD3^+$ $CD8^+$ T cells followed, and $\mathrm{CD4^+}$ and $\mathrm{CD8^+}$ T-cell subsets were identified. Isotype control was performed by using mouse immunoglobulin G (mouse-IgG) Allophycocyanin and mouse-IgG R-Phycoerythrin (BioLegend) for a better discrimination of CTLA-4 and CD25.

The other populations could be easily discriminated. After blocking with 25 μ g/mL of normal mouse IgG (Sigma-Aldrich, Co., St. Louis, MO) for 15 minutes on ice, all the cells underwent cell surface staining, followed by intracellular staining. For intracellular staining of FoxP3 and CTLA-4, all the cells were treated with fixation buffer for 30 minutes at room tempera-

Table 1Baseline characteristics of the study group			
Clinical Feature	Study Group		
Patients, no.	11		
mean age, mean \pm SD, y	53.27 ± 15.84		
Women/men	4/7		
Previous surgery, no. (%)	3 (27.27)		
Eosinophilic polyps, no. (%)	10 (90,01)		
Allergy, no. (%)	4 (36,36)		
Samter triad, no. (%)	1 (9.09)		
SD = Standard deviation.			

ture (eBioscence). Afterward, permeabilization buffer was applied (eBioscence), followed by staining with anti-FoxP3 and anti–CTLA-4 for 45 minutes at room temperature. All the antibodies were used according to the manufacturers' instructions. Flow cytometry analysis was performed by using an LSR II flow cytometer (Becton, Dickinson and Co., San Diego, CA), and data were analyzed by using FlowJo software (TreeStar, Ashland, OR).

Ethics Issues

The study was approved by the ethics board of the Medical Faculty, Julius-Maximilian-University Wuerzburg (12/06), and all the participants gave written informed consent. All the authors significantly contributed to this work.

Statistics

Data are presented as mean \pm standard deviation (SD). Statistical significance was analyzed by a twotailed paired *t*-test by using GraphPad Prism Software 6.0c (GraphPad Software Inc., La Jolla, California). For nonparametric distribution, the Wilcoxon test was applied. Values of p < 0.05 were considered to be statistically significant.

RESULTS

Patient Characteristics

Eleven patients were included in the study group (seven male and four female patients). All the patients received intranasal topical steroids before surgery. The treatment started weeks before surgery, and, if the patients did not benefit from this medical therapy, then a surgical intervention was planned, according to the European guideline suggestions.²⁶ Patients with Churg-Strauss syndrome, primary ciliary dyskinesia, or cystic fibrosis were excluded. The mean \pm SD age was 53.27 \pm 15.84 years. Eosinophilic polyposis was described in the histologic evaluation of most of the patients (10/11). The characteristics are summarized in Table 1.

Predominance of Effector and/or Memory Cells among CD4⁺ and CD8⁺ T-cell Subsets in Nasal Polyps

The number of isolated lymphocytes from healthy nasal mucosa was too low for the multicolor flow cytometry panel. Lymphocytes of nasal polyps and peripheral blood from the 11 patients were analyzed by flow cytometry. After separating all apoptotic cells, there was a significantly lower amount of CD3⁺ CD4⁺ T cells and a significantly higher amount of CD3⁺ CD3⁺ CD8⁺ T cells in nasal polyps compared with peripheral blood mononuclear cells (PBMCs) (Fig. 1 *A*; Table 2).

Further analyses of CD3⁺ CD4⁺ T cells showed significantly lower frequencies of CCR7⁺ CD45RA⁺ naive and CCR7⁺ CD45⁻ central memory T cells in nasal polyps compared with PBMCs (Table 2). The proportion of CCR7⁻ CD45RA⁻ effector memory Th cells was significantly higher in nasal polyps (Fig. 1 *B*; Table 2). There was no statistically significant difference in the frequency of CCR7⁻ CD45RA⁺ terminally differentiated T cells (Fig. 1 B; Table 2). This result was consistent with the amounts of CD45RA⁺ CD28⁻ terminally differentiated T cells without statistical significance $(0.43 \pm 0.75\% \text{ PBMC}, 1.6 \pm 2.79\% \text{ nasal polyps})$ between both study groups. CD4⁺ CD25⁻ CD45RA⁻ memory Th cells were significantly higher in nasal polyps (44.11 ± 13.20% PBMC, 77.33 ± 8.00% nasal polyps), and a significantly lower fraction of CD4⁺ CD25⁻ CD45RA⁺ naive Th cells was observed in the polyps (36.60 ± 15.57% PBMC, 7.71 ± 2.65% nasal polyps).

Quantitative analysis of CD3⁺ CD8⁺ T cells showed significantly lower frequencies of CCR7⁻ CD45RA⁺ terminally differentiated and CCR7⁺ CD45RA⁺ naive subpopulations among these cells in nasal polyps, whereas CCR7⁻ CD45RA⁻ effector memory (cytotoxic) T cells were significantly higher in nasal polyps (Fig. 1 *C*; Table 2). CCR7⁺ CD45RA⁻ central memory cytotoxic T cells were significantly lower in nasal polyps (Fig. 1 *C*; Table 2). CD45RA⁺ CD28⁻ terminally differentiated T cells were also significantly higher in PBMC (12.73 \pm 6.94% PBMC, 4.97 \pm 4.95% nasal polyps). However, there was no statistically significant difference in the upregulation of the marker for activation HLA-DR²⁴ on CD3⁺ T cells (Fig. 1 *D*) between both groups (2.69 \pm 1.16% PBMC, 4.06 \pm 1.9% nasal polyps).

Significant Increase in aT_{reg} Cells and Nonsuppressive Conventional FoxP3^{low} Memory T Cells in Nasal Polyps compared with PBMC

Most of the CD3⁺ CD4⁺ T cells were FoxP3⁻ in both groups (Fig. 2 *A*; Table 3). In detail, there were significantly lower frequencies of CD3⁺ CD4⁺ CD45RA⁺ FoxP3⁻ naive T cells and significantly higher frequencies of CD3⁺ CD4⁺ CD45RA⁻ FoxP3⁻ memory T cells



Figure 1. (*A*) $CD8^+$ and $CD4^+$ T cells in PBMC and nasal polyps. (B) $CD4^+$ T cell subsets in PBMC and nasal polyps. (C) $CD8^+$ T cell subsets in PBMC and nasal polyps. (D) Upregulation of HLA-DR on $CD3^+$ T cells in PBMC and nasal polyps. Data are shown as means \pm standard deviations (SD) of the 11 patients. PBMC = peripheral blood mononuclear cells; HLA-DR = human leukocyte antigen - antigen D related.

T Cells	PBMC, mean ± SD*	Nasal Polyps, mean ± SD*	p Value#
CD4 ^{+(%)}	46.38 ± 9.27	19.15 ± 7.73	< 0.0001
CD45RA ⁻ CCR7 ⁻ effector memory	35.57 ± 13.27	76.72 ± 18.84	0.002
CD45RA ⁺ CCR7 ⁻ terminal differentiated	2.81 ± 1.63	9.76 ± 20.23	0.052
CD45RA ⁻ CCR7 ⁺ central memory	25.62 ± 8.04	9.18 ± 7.28	0.001
CD45RA ⁺ CCR7 ⁺ naive	36.00 ± 14.40	4.35 ± 3.36	0.001
CD8 ^{+(%)}	18.65 ± 8.91	34.44 ± 14.11	0.003
CD45RA ⁻ CCR7 ⁻ effector memory	11.34 ± 7.52	56.82 ± 17.62	< 0.0001
CD45RA ⁺ CCR7 ⁻ terminally differentiated	45.96 ± 14.55	30.94 ± 17.59	0.0056
CD45RA ⁻ CCR7 ⁺ central memory	16.49 ± 14.55	9.39 ± 5.73	0.025
CD45RA ⁺ CCR7 ⁺ naive	26.31 ± 10.28	2.83 ± 1.90	< 0.0001
PBMC = peripheral blood mononuclear cells; SD =	standard deviation; CD45	RA = cluster of differentiation 45R	RA; CCR7 =

Table 2**CD3+** T cell subpopulations

PBMC = peripheral blood mononuclear cells; SD = standard deviation; CD45RA = cluster of differe C-C chemokine receptor type 7. *Of the 11 patients.

#Paired t-test.

#Pulreu I-lest.

in nasal polyps compared with peripheral blood (Fig. 2 *A*; Table 3). CD3⁺ CD4⁺ CD45RA⁻ FoxP3^{high} aT_{reg} and CD3⁺ CD4⁺ CD45RA⁻ FoxP3^{low} memory T cells were significantly higher in nasal polyps, but CD3⁺ CD4⁺ CD45RA⁺ FoxP3^{low} rT_{reg} cells were not elevated in nasal polyps (Fig. 2 *A*; Table 3). The mean fluorescence intensity of CTLA-4 was high on aT_{reg} cells and low on rT_{reg} cells in both groups (Fig. 3 *A*). To determine whether there is a mismatch of conventional CD45RA⁻ FoxP3^{low} memory, CD45RA⁻ FoxP3⁻ memory, and CD45RA⁺ FoxP3⁻ naive CD4⁺ T cells or CD8⁺ T cells to T_{reg} cells (aT_{reg} and rT_{reg}), the ratio of these cells was calculated (Fig. 3 *B*). The ratio of conventional CD4⁺ T cells to T_{reg} cells was significantly higher in peripheral blood than in nasal polyps.

DISCUSSION

In this study, a detailed quantification of the subpopulations of T lymphocytes in peripheral blood and nasal polyps in CRSwNP was presented. As previously shown, there was a switch from mainly CD4⁺ T cells among peripheral blood $\alpha\beta$ T cells to mainly cytotoxic CD8⁺ T cells in nasal polyps, with a significant domination of effector T cells among both CD4⁺ and CD8⁺ T cells in nasal polyps compared with peripheral blood.^{27–29} Moreover, aT_{reg} cells were significantly increased among CD4⁺ T cells in nasal polyps compared with peripheral blood in patients with CRSwNP.

CD4⁺ Th cells can exhibit different properties, depending on their differentiation into one of the following Th1, Th2 or Th17 subsets. However, newer studies showed a variation in different T-cell subtypes present in the infected nasal mucosa but with a predominant Th1 subset in CRSsNP and Th2 subset in CRSwNP.^{29–31} Th17 T cells act synergistically with the other subsets and produce, especially interleukin (IL)

17, IL-21, IL-22, and IL-26. Among patients with CRSwNP, demographic variation seemed to play an additional role with respect to T-cell subdivision: Th2biased cytokine profiles were mostly found in patients from Europe and the United States, whereas Th1:Th17 profiles were predominantly found in Asian patients.²⁵

In the present study, the majority of T lymphocytes in nasal polyps were $CD8^+$ T cells with an effector memory phenotype. These findings underscored the importance of $CD8^+$ cytotoxic T-cell responses in the pathogenesis of nasal polyps. The role of $CD8^+$ T cells in the defense against viruses and intracellular bacteria is clearly understood, but their role in allergic diseases is not yet completely known. Tang *et al.*³² described effector $CD8^+$ T cells as dampening allergic responses in the effector phase. In contrast, there are other studies that identify effector memory $CD8^+$ T cells as pathogenic in allergic responses.^{33,34}

Because fungal and bacterial colonization of the local nasal mucosa has been identified to have at least contributed to T-cell recruitment into polyps,^{4–11} we were curious to study HLA-DR expression as a marker of recent T-cell activation. In contrast to their overall activated phenotype, the edaphic CD3⁺ T cells did not show any increased HLA-DR expression compared with blood T cells. This lack in HLA-DR upregulation might be caused by differentiation of the CD4⁺ and CD8⁺ T-cell subsets outside the polyp tissue in lymphoid organs without a restimulation of the T cells within the nasal polyp itself. Tissue-resident CD8⁺ T cells have been shown in mice to be maintained in situ, without local antigenic restimulation,³⁵ and antifungal memory CD8⁺ T cells have also been shown to survive in the absence of antigen or CD4⁺ T-cell help.³⁶ Alternatively, the preoperative treatment with local or systemic corticoids inhibits the upregulation of HLA-DR



Figure 2. Regulatory T cell (T_{reg}) subpopulations in PBMC and nasal polyps. (A) Frequency of CD4⁺ resting T_{reg} (rT_{reg}), activated T_{reg} (aT_{reg}), and FoxP3^{low} memory T cells in PBMC and nasal polyps. (B) Expression of CTLA-4 by FoxP3⁺ cells in PBMC and nasal polyps. (C) CD4⁺ CD25⁺ FoxP3⁺ activated T_{reg} in PBMC and nasal polyps. Data are shown as means \pm standard deviations (SD) of the 11 patients. PBMC = peripheral blood mononuclear cells; FoxP3^{low} = low expressive Forkhead-Box-Protein P3; CTLA-4 = cytotoxic T-lymphocyte-associated Protein 4; FoxP3⁺ = Forkhead-Box-Protein P3.

and reactivation of the T cells. Moreover, corticoid treatment might also have had a differential impact on T_{reg} cells and conventional T cells, although information about the effects of glucocorticoids on functional properties of T_{reg} cells is inconsistent in the literature. Some investigators see an increase in T_{reg} cells after glucocorticoid therapy.³⁷ However, in contrast, de Paz *et al.*³⁸ described interindividually different responses of T_{reg} cells to glucocorticoids among different patients, and Tabares *et al.*³⁹ showed T_{reg} cells to be

relatively resistant to the immunosuppressive actions of glucocorticoids, which seemed to be in line with the present study findings.

 T_{reg} cells play an important role in maintaining peripheral tolerance to self-antigens and in counteracting the inflammatory activity of effector Th cell subsets.³⁷ Classically, T_{reg} cells were analyzed by staining for CD4, CD25, and FoxP3 expression. As previously mentioned, Miyara *et al.*²² described a revised classification of CD4⁺ FoxP3⁺ T cells into FoxP3^{high} aT_{reg}, FoxP3^{low}

Table 3 Tree subpopulations analyzed by staining of CD4, CD45RA, FoxP3, and CTLA-4					
CD3 ⁺ CD4 ⁺ T Cells	PBMC, mean ± SD*, %	Nasal Polyps, mean ± SD*, %	p Value#		
CD45RA ⁺ FoxP3 ^{low} CTLA-4 ^{low} resting T _{reg} cells	1.24 ± 0.51	1.93 ± 2.44	0.38		
CD45RA ⁻ FoxP3 ^{high} CTLA-4 ^{high} activated T _{reg} cells	0.60 ± 0.70	2.57 ± 1.81	0.0029		
CD45RA [–] FoxP3 ^{low} memory T cells	5.03 ± 1.34	8.87 ± 4.08	0.002		
CD45RA ⁻ FoxP3 ⁻ memory T cells	54.45 ± 15.44	78.49 ± 6.20	0.0007		
CD45RA ⁺ FoxP3 ⁻ naive T cells	38.85 ± 15.65	8.00 ± 2.78	0.0001		

 T_{reg} = regulatory T; CD45RA = cluster of differentiation 45RA; FoxP3 = Forkhead-Box-Protein P3; CTLA-4 = cytotoxic T-lymphocyte-associated Protein 4; PBMC = peripheral blood mononuclear cell; SD = standard deviation; FoxP3^{low} = low expression of Forkhead-Box-Protein P3; FoxP3^{high} = high expression of Forkhead-Box-Protein P3; CTLA-4^{low} = low expression of cytotoxic T-lymphocyte-associated Protein 4; CTLA-4^{high} = high expression of cytotoxic T-lymphocyte-associated Protein 4. *Of the 11 patients. #Paired t-test.



Figure 3. (A) Mean fluorescence intensity (MFI) of CTLA-4 on FoxP3⁺ T cells in PBMC and nasal polyps. (B) Ratio of conventional T cells to regulatory T cells in CD4⁺ and CD8⁺ T cells. Data are shown as means \pm standard deviations (SD) of the 11 patients. CTLA-4 = cytotoxic T-lymphocyte-associated Protein 4; oxP3^{high} = high expression of Forkhead-Box-Protein P3.

rT_{reg}, and conventionally nonsuppressive Foxp3^{low} memory T cells. The FoxP3^{low} memory T cells contain Th17 T cells and are not suppressive. Moreover, within the three subpopulations described, FoxP3^{low} memory T cells had the highest frequencies in our study, which indicated that the Th17 pathway might also be important in the CRSwNP pathogenesis, even in patients of European descent. Apart from FoxP3^{low} memory T cells, we found significantly more aTreg cells among CD4⁺ T cells in polyp tissue compared with T cells from peripheral blood (Fig. 2). Furthermore, we found a significantly lower ratio of conventional memory and naive CD4⁺ T cells to T_{reg} cells in nasal polyps than in PBMC. This indicated that T_{reg} cells should be able to efficiently suppress local CD4⁺ T-cell responses in the polyp and might thereby prevent further exacerbation of the disease. In contrast, the CD8⁺:T_{reg} ratio was not

significantly different in nasal polyps compared with peripheral blood, which indicated that T_{reg} cells might be less able to control CD8⁺ T cells than conventional CD4⁺ T cells in polyps.

To our knowledge, this study provided the first comparison of different T_{reg} cell subpopulations in peripheral blood and nasal polyps when using multicolor flow cytometry. A previous study on T_{reg} cells in CRSwNP used flow cytometry to characterize T_{reg} cells in peripheral blood and two-color immunohistochemistry to detect T_{reg} in nasal polyps.¹⁷ Other studies focused on the nasal mucosa and/or polyps by using immunohistochemistry to detect T_{reg} cells^{2,12} Although T_{reg} cell frequencies in peripheral blood in healthy subjects and in patients with CRSwNP do not seem to differ,¹⁷ the two studies that analyzed T_{reg} cells in the mucosa reported a decrease in absolute as well as relative numbers compared with patients with CRSsNP and mucosal tissue from controls.^{2,12} In these studies, however, FoxP3 expression alone was used to identify T_{reg} cells. Because our own analyses revealed that the majority of CD4⁺ FoxP3⁺ cells in nasal polyps were nonregulatory memory T cells, further studies are needed to determine the abundance of T_{reg} cells in polyps versus mucosal tissues of patients with CRSsNP and "healthy" controls.

The results of this study were limited by (1) the small number of subjects, and (2) there not being a control group of healthy nasal mucosa. The study was declared to be a pilot project with a limited amount of samples. Because there was no control group with healthy mucosa, interpretation of the data was affected. For example, a significantly lower ratio of conventional memory and naive $CD4^+$ T cells to T_{reg} cells in nasal polyps compared with PBMC in patients with CRSwNP was observed. But, if the ratio of conventional T cells to T_{reg} cells were much lower in healthy control tissue than in polyps, this would indicate that there are not enough T_{reg} cells in the polyps. Without a control group of healthy mucosa, it was difficult to provide further mechanistic insight. Unfortunately, analysis of lymphocytes from healthy nasal mucosa failed due to low amounts of these cells in this noninflammatory tissue, and high cell amounts are necessary for this multicolor flow cytometry analysis. When assuming that most of the lymphocytes in healthy nasal mucosa were circulating intravascular cells, a control group of PBMC seemed to be equivalent, and, furthermore, a comparison of isolated T cells from tissue with PBMC is well established in the literature.^{23,40}

CONCLUSION

In this study, a detailed contemporary characterization of T-cell subpopulations was presented. CD8⁺ (cytotoxic) T cells are the main subpopulation in nasal polyps. Both CD8⁺ T cells and CD4⁺ T cells showed differentiation into a more effector memory phenotype. T_{reg} cells are important for immune homeostasis and aT_{reg} cells were increased relative to conventional CD4⁺ T cells but not to CD8⁺ T cells in nasal polyps compared with peripheral blood, which indicated that a failure of T_{reg} cells to control the CD8⁺ T cell response in the polyp might contribute to the development of nasal polyposis.

REFERENCES

- Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: Inflammation. J Allergy Clin Immunol 128:728–732, 2011.
- Shi J, Fan Y, Xu R, et al. Characterizing T-cell phenotypes in nasal polyposis in Chinese patients. J Invest Allergol Clin Immunol 19:276–282, 2009.
- 3. Stuck BA, Bachert C, Federspil P, et al. Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and

Neck Surgery [in German]. HNO 55:758–760, 762–764, 766–777, 2007.

- Pant H, Beroukas D, Kette FE, et al. Nasal polyp cell populations and fungal-specific peripheral blood lymphocyte proliferation in allergic fungal sinusitis. Am J Rhinol Allergy 23:453– 460, 2009.
- Pant H, and Macardle P. CD8(+) T cells implicated in the pathogenesis of allergic fungal rhinosinusitis. Allergy Rhinol (Providence) 5:146–156, 2014.
- Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clinic Proc 74:877– 884, 1999.
- Bachert C, Zhang N, Patou J, et al. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol 8:34–38, 2008.
- Van Zele T, Gevaert P, Watelet JB, et al. *Staphylococcus aureus* colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 114:981–983, 2004.
- Wang M, Shi P, Yue Z, et al. Superantigens and the expression of T-cell receptor repertoire in chronic rhinosinusitis with nasal polyps. Acta Otolaryngol 128:901–908, 2008.
- Conley DB, Tripathi A, Seiberling KA, et al. Superantigens and chronic rhinosinusitis: Skewing of T-cell receptor V beta-distributions in polyp-derived CD4+ and CD8+ T cells. Am J Rhinol 20:534–539, 2006.
- Conley DB, Tripathi A, Seiberling KA, et al. Superantigens and chronic rhinosinusitis II: Analysis of T-cell receptor V beta domains in nasal polyps. Am J Rhinol 20:451–455, 2006.
- Kim YM, Munoz A, Hwang PH, et al. Migration of regulatory T cells toward airway epithelial cells is impaired in chronic rhinosinusitis with nasal polyposis. Clin Immunol 137:111–121, 2010.
- Bacher P, Kniemeyer O, Schonbrunn A, et al. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol 7:916– 928, 2014.
- Bacher P, Kniemeyer O, Teutschbein J, et al. Identification of immunogenic antigens from *Aspergillus fumigatus* by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J Immunol 193:3332–3343, 2014.
- 15. Broker BM, Mrochen D, and Peton V. The T cell response to *Staphylococcus aureus*. Pathogens 5:pii: E31, 2016.
- 16. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 133:775–787, 2008.
- 17. Sharma S, Watanabe S, Sivam A, et al. Peripheral blood and tissue T regulatory cells in chronic rhinosinusitis. Am J Rhinol Allergy 26:371–379, 2012.
- Robinson DS. The role of regulatory T lymphocytes in asthma pathogenesis. Curr Allergy Asthma Rep 5:136–141, 2005.
- Jie HB, Schuler PJ, Lee SC, et al. CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75:2200–2210, 2015.
- Roychoudhuri R, Eil RL, and Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 33:101–111, 2015.
- 21. Pant H, Hughes A, Schembri M, et al. CD4(+) and CD8(+) regulatory T cells in chronic rhinosinusitis mucosa. Am J Rhinol Allergy 28:e83–e89, 2014.
- Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911, 2009.
- 23. Rau M, Schilling AK, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased

Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol 196:97–105, 2016.

- 24. Maecker HT, McCoy JP, and Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 12:191–200, 2012.
- Bachert C, Zhang L, and Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol 136:1431–1440; quiz 1441, 2015.
- Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50:1–12, 2012.
- Huang Z, Nayak JV, Sun Y, et al. Peripheral blood T-helper cells and eosinophil populations in patients with atopic and nonatopic chronic rhinosinusitis. Am J Rhinol Allergy 31:8–12, 2017.
- Pant H, Hughes A, Miljkovic D, et al. Accumulation of effector memory CD8+ T cells in nasal polyps. Am J Rhinol Allergy 27:e117–e126, 2013.
- 29. Derycke L, Eyerich S, Van Crombruggen K, et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PLoS One 9:e97581, 2014.
- Annunziato F, and Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 11:257, 2009.
- Otto BA, and Wenzel SE. The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg 16:270–274, 2008.
- Tang Y, Guan SP, Chua BY, et al. Antigen-specific effector CD8 T cells regulate allergic responses via IFN-gamma and dendritic cell function. J Allergy Clin Immunol 129:1611–1620.e4, 2012.

- Miyahara N, Swanson BJ, Takeda K, et al. Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nature Med 10:865–869, 2004.
- Taube C, Miyahara N, Ott V, et al. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 176: 3157–3164, 2006.
- Schenkel JM, and Masopust D. Tissue-resident memory T cells. Immunity 41:886–897, 2014.
- Nanjappa SG, Heninger E, Wuthrich M, et al. Protective antifungal memory CD8(+) T cells are maintained in the absence of CD4(+) T cell help and cognate antigen in mice. J Clin Invest 122:987–999, 2012.
- Lochner M, Wang Z, and Sparwasser T. The special relationship in the development and function of T helper 17 and regulatory T cells. Prog Mol Biol Transl Sci 136:99–129, 2015.
- de Paz B, Alperi-Lopez M, Ballina-Garcia FJ, et al. Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J Rheumatol 37:2502– 2510, 2010.
- Tabares P, Berr S, Romer PS, et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol 44:1225–1236, 2014.
- Murray T, Fuertes Marraco SA, Baumgaertner P, et al. Very late antigen-1 marks functional tumor-resident CD8 T cells and correlates with survival of melanoma patients. Front Immunol 7:573, 2016. □